GlassScriptPhysician profile
Matthew A Mccoyd
NPI 1932346566
$206,422.44
in general payments reported to CMS, 2019-2025
16 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $26K · 2021: $17K · 2022: $22K · 2023: $32K · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $7,788 · Food and Beverage: $4,343 · Travel and Lodging: $2,757 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,568.00 |
| Consulting Fee | $7,788.00 |
| Food and Beverage | $4,342.60 |
| Travel and Lodging | $2,757.23 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $98,261.67 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $79,066.87 | 2019-2025 | |
| Biogen, INC. | $12,890.95 | 2019 | |
| Amgen INC. | $7,959.23 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $2,365.02 | 2019-2024 | |
| Genentech USA, INC. | $2,185.00 | 2020 | |
| Genentech, INC. | $1,260.00 | 2021 | |
| Argenx US, INC. | $1,188.00 | 2023 | Vyvgart |
| E.R. Squibb & Sons, L.L.C. | $639.84 | 2021-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $194.60 | 2021-2025 | |
| Abbvie INC. | $124.41 | 2025 | |
| Alexion Pharmaceuticals, INC. | $97.56 | 2023 | |
| Celgene Corporation | $86.42 | 2023-2025 | Zeposia |
| Tg Therapeutics, INC. | $67.96 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mccoyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.